Restricted accessResearch articleFirst published online 2017-12
The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder
This study sought to reproduce, in a larger sample, previous findings of a correlation between smaller raw 3-Tesla (3T) hippocampal volumes and improved antidepressant efficacy of ketamine in individuals with major depressive disorder (MDD). A secondary analysis stratified subjects according to functional BDNF rs6265 (val66met) genotype.
Methods:
Unmedicated subjects with treatment-resistant MDD (n=55) underwent baseline structural 3T MRI. Data processing was conducted with FSL/FIRST and Freesurfer software. The amygdala, hippocampus, and thalamus were selected a priori for analysis. All subjects received a single 0.5mg/kg × 40-minute ketamine infusion. Pearson correlations were performed with subcortical volumes and percent change in MADRS score (from baseline to 230 minutes, 1 day, and 1 week post-infusion).
Results:
Raw and corrected subcortical volumes did not correlate with antidepressant response at any timepoint. In val/val subjects (n=23), corrected left and right thalamic volume positively correlated with antidepressant response to ketamine at 230 minutes post-infusion but did not reach statistical significance. In met carriers (n=14), corrected left and right thalamic volume negatively correlated with antidepressant response to ketamine.
Conclusion:
Baseline subcortical volumes implicated in MDD did not correlate with ketamine’s antidepressant efficacy. Baseline thalamic volume and BDNF genotype may be a combinatorial rapid antidepressant response biomarker.
AbdallahCGSalasRJackowskiAet al. (2015a) Hippocampal volume and the rapid antidepressant effect of ketamine. J Psychopharmacol29: 591–595.
2.
AbdallahCGSanacoraGDumanRSet al. (2015b) Ketamine and rapid-acting antidepressants: A window into a new neurobiology for mood disorder therapeutics. Annu Rev Med66: 509–523.
3.
ArnoneDMcKieSElliottRet al. (2013) State-dependent changes in hippocampal grey matter in depression. Mol Psychiatry18: 1265–1272.
BermanRMCappielloAAnandAet al. (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry47: 351–354.
6.
ChiMHChangHHLeeSYet al. (2010) Brain derived neurotrophic factor gene polymorphism (val66met) and short-term antidepressant response in major depressive disorder. J Affect Disord126: 430–435.
7.
ChoiMJKangRHLimSWet al. (2006) Brain-derived neurotrophic factor gene polymorphism (val66met) and citalopram response in major depressive disorder. Brain Res1118: 176–182.
8.
ColleRGressierFVerstuyftCet al. (2015) Brain-derived neurotrophic factor val66met polymorphism and 6-month antidepressant remission in depressed Caucasian patients. J Affect Disord175: 233–240.
9.
CoyleCMLawsKR (2015) The use of ketamine as an antidepressant: A systematic review and meta-analysis. Hum Psychopharmacol30: 152–163.
10.
DiazgranadosNIbrahimLBrutscheNEet al. (2010) A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry67: 793–802.
11.
EganMFKojimaMCallicottJHet al. (2003) The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell112: 257–269.
12.
El-HageWVourc’hPGaillardPet al. (2015) The BDNF Val(66)Met polymorphism is associated with escitalopram response in depressed patients. Psychopharmacology (Berl)232: 575–581.
13.
FirstMBSpitzerRLGibbonMet al. (2002) Structured Clinical Interview for DSM-IV-TR Axis I Disorders Research Version, Patient Edition with Psychotic Screen (SCID-I/P). New York, NY: Biometrics Research, New York State Psychiatric Institute.
14.
FischlBDaleAM (2000) Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci U S A97: 11050–11055.
15.
FrodlTJagerMSmajstrlovaIet al. (2008) Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: A 3-year prospective magnetic resonance imaging study. J Psychiatry Neurosci33: 423–430.
16.
FrodlTSchuleCSchmittGet al. (2007) Association of the brain-derived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression. Arch Gen Psychiatry64: 410–416.
17.
GonulASKitisOEkerMCet al. (2011) Association of the brain-derived neurotrophic factor Val66Met polymorphism with hippocampus volumes in drug-free depressed patients. World J Biol Psychiatry12: 110–118.
18.
HaileCNMurroughJWIosifescuDVet al. (2014) Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. Int J Neuropsychopharmacol17: 331–336.
19.
HamiltonJPSiemerMGotlibIH (2008) Amygdala volume in major depressive disorder: A meta-analysis of magnetic resonance imaging studies. Mol Psychiatry13: 993–1000.
20.
HsiehMHMcQuoidDRLevyRMet al. (2002) Hippocampal volume and antidepressant response in geriatric depression. Int J Geriatr Psychiatry17: 519–525.
21.
HwangJPTsaiSJHongCJet al. (2006) The val66met polymorphism of the brain-derived neurotrophic factor gene is associated with geriatric depression. Neurobiol Aging27: 1834–1837.
22.
IbrahimLDiazgranadosNFranco-ChavesJet al. (2012) Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: Results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology37: 1526–1533.
23.
JenkinsonMBannisterPBradyMet al. (2002) Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage17: 825–841.
24.
JoshiSHEspinozaRTPirniaTet al. (2016) Structural plasticity of the hippocampus and amygdala induced by electroconvulsive therapy in major depression. Biol Psychiatry79: 282–292.
25.
KanellopoulosDGunningFMMorimotoSSet al. (2011) Hippocampal volumes and the brain-derived neurotrophic factor val66met polymorphism in geriatric major depression. Am J Geriatr Psychiatry19: 13–22.
26.
KangRHChangHSWongMLet al. (2010) Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression. J Psychopharmacol24: 1755–1763.
27.
KishimotoTChawlaJMHagiKet al. (2016) Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: A meta-analysis of efficacy, safety and time trajectories. Psychol Med46: 1459–1472.
28.
LajeGLallyNMathewsDet al. (2012) Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol Psychiatry72: e27–28.
29.
LangUEHellwegRSanderTet al. (2009) The Met allele of the BDNF Val66Met polymorphism is associated with increased BDNF serum concentrations. Mol Psychiatry14: 120–122.
30.
LiNLeeBLiuRJet al. (2010) mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science329: 959–964.
LiuRJLeeFSLiXYet al. (2012) Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry71: 996–1005.
33.
MacQueenGMYucelKTaylorVHet al. (2008) Posterior hippocampal volumes are associated with remission rates in patients with major depressive disorder. Biol Psychiatry64: 880–883.
MontgomerySAAsbergM (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry134: 382–389.
36.
MurroughJWIosifescuDVChangLCet al. (2013a) Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial. Am J Psychiatry170: 1134–1142.
37.
MurroughJWPerezAMPillemerSet al. (2013b) Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry74: 250–256.
38.
NewportDJCarpenterLLMcDonaldWMet al. (2015) Ketamine and other NMDA antagonists: Early clinical trials and possible mechanisms in depression. Am J Psychiatry172: 950–966.
NiciuMJLuckenbaughDAIonescuDFet al. (2014b) Ketamine’s antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder. Int J Neuropsychopharmacol18: pii: pyu039.
41.
NiciuMJMathewsDCNugentACet al. (2014c) Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants. Depress Anxiety31: 297–307.
42.
NugentACDavisRMZarateCAJret al. (2013a) Reduced thalamic volumes in major depressive disorder. Psychiatry Res213: 179–185.
43.
NugentACLuckenbaughDAWoodSEet al. (2013b) Automated subcortical segmentation using FIRST: Test-retest reliability, interscanner reliability, and comparison to manual segmentation. Hum Brain Mapp34: 2313–2329.
PatenaudeBSmithSMKennedyDNet al. (2011) A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage56: 907–922.
46.
PennybakerSJNiciuMJLuckenbaughDAet al. (2017) Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion. J Affect Disord208: 560–566.
47.
PeriniGIToffaninTPigatoGet al. (2017) Hippocampal gray volumes increase in treatment-resistant depression responding to vagal nerve stimulation. J ECT33:160–166.
48.
PhillipsJLBattenLATremblayPet al. (2015) A prospective, longitudinal study of the effect of remission on cortical thickness and hippocampal volume in patients with treatment-resistant depression. Int J Neuropsychopharmacol18: pii: pyv037.
49.
SackeimHA (2001) The definition and meaning of treatment-resistant depression. J Clin Psychiatry62Suppl 16: 10–17.
50.
SchermulyIWolfDLiebKet al. (2011) State dependent posterior hippocampal volume increases in patients with major depressive disorder. J Affect Disord135: 405–409.
51.
TrivediMHRushAJWisniewskiSRet al. (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry163: 28–40.
52.
VakiliKPillaySSLaferBet al. (2000) Hippocampal volume in primary unipolar major depression: A magnetic resonance imaging study. Biol Psychiatry47: 1087–1090.
53.
ValentineGWMasonGFGomezRet al. (2011) The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res191: 122–127.
54.
WadeBSJoshiSHNjauSet al. (2016) Effect of electroconvulsive therapy on striatal morphometry in major depressive disorder. Neuropsychopharmacology41: 2481–2491.
55.
ZarateCAJrBrutscheNEIbrahimLet al. (2012) Replication of ketamine’s antidepressant efficacy in bipolar depression: A randomized controlled add-on trial. Biol Psychiatry71: 939–946.
56.
ZarateCAJrMathewsDCFureyML (2013) Human biomarkers of rapid antidepressant effects. Biol Psychiatry73: 1142–1155.
57.
ZarateCAJrSinghJBCarlsonPJet al. (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry63: 856–864.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
